1. Home
  2. SNGX vs OFAL Comparison

SNGX vs OFAL Comparison

Compare SNGX & OFAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • OFAL
  • Stock Information
  • Founded
  • SNGX 1987
  • OFAL 2013
  • Country
  • SNGX United States
  • OFAL United States
  • Employees
  • SNGX N/A
  • OFAL N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • OFAL Military/Government/Technical
  • Sector
  • SNGX Health Care
  • OFAL Consumer Discretionary
  • Exchange
  • SNGX Nasdaq
  • OFAL Nasdaq
  • Market Cap
  • SNGX 13.8M
  • OFAL 14.1M
  • IPO Year
  • SNGX 1987
  • OFAL 2025
  • Fundamental
  • Price
  • SNGX $1.48
  • OFAL $0.70
  • Analyst Decision
  • SNGX Strong Buy
  • OFAL
  • Analyst Count
  • SNGX 1
  • OFAL 0
  • Target Price
  • SNGX $6.00
  • OFAL N/A
  • AVG Volume (30 Days)
  • SNGX 256.3K
  • OFAL 111.9K
  • Earning Date
  • SNGX 11-07-2025
  • OFAL 12-05-2025
  • Dividend Yield
  • SNGX N/A
  • OFAL N/A
  • EPS Growth
  • SNGX N/A
  • OFAL N/A
  • EPS
  • SNGX N/A
  • OFAL N/A
  • Revenue
  • SNGX N/A
  • OFAL $202,007.00
  • Revenue This Year
  • SNGX N/A
  • OFAL N/A
  • Revenue Next Year
  • SNGX N/A
  • OFAL N/A
  • P/E Ratio
  • SNGX N/A
  • OFAL N/A
  • Revenue Growth
  • SNGX N/A
  • OFAL N/A
  • 52 Week Low
  • SNGX $1.09
  • OFAL $0.60
  • 52 Week High
  • SNGX $6.23
  • OFAL $9.79
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 47.15
  • OFAL N/A
  • Support Level
  • SNGX $1.25
  • OFAL N/A
  • Resistance Level
  • SNGX $1.47
  • OFAL N/A
  • Average True Range (ATR)
  • SNGX 0.11
  • OFAL 0.00
  • MACD
  • SNGX 0.02
  • OFAL 0.00
  • Stochastic Oscillator
  • SNGX 65.45
  • OFAL 0.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About OFAL OFA Group Ordinary Shares

OFA Group, through its subsidiary, provides architectural services, including design and fit-out services for commercial and residential buildings in Hong Kong. The design service includes both the consultation with staff and the actual design work and the company provides a specific conceptualized design with layout plans, detailed design drawings, advice relating to, among other things, budgetary consideration, optimal use of space, the materials, fittings, furniture, appliances and other items to be used to produce a preliminary design plan and quotation. Its works include installing protective materials to cover floors or walls, installing or constructing partition walls, windows, window frames, and decorative fittings, furniture or fixtures, installing plumbing systems, etc.

Share on Social Networks: